Compare Stocks → Start loving Mondays like this (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATXINASDAQ:COCPNASDAQ:ORMPOTCMKTS:PVOTFNASDAQ:VBLT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.13-4.3%$0.15$0.11▼$1.25$5.70M-0.244.53 million shs214,043 shsCOCPCocrystal Pharma$1.60+7.0%$1.49$1.33▼$3.29$16.27M1.3413,642 shs5,233 shsORMPOramed Pharmaceuticals$2.28+3.6%$2.92$1.67▼$5.25$92.39M1.81170,805 shs75,501 shsPVOTFBetterLife Pharma$0.13$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsVBLTVascular Biogenics$5.46-8.8%$0.40$0.10▼$6.74$423.91M0.772.19 million shs161,505 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics-0.37%-4.67%-15.88%-3.93%-87.54%COCPCocrystal Pharma+2.80%-5.16%+3.52%-9.26%-41.90%ORMPOramed Pharmaceuticals-5.58%-14.73%-22.26%-0.90%-3.51%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%VBLTVascular Biogenics0.00%0.00%0.00%0.00%+2,547.91%Start loving Mondays like this (Ad)Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!Weekend after weekend!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXIAvenue TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACOCPCocrystal Pharma2.5419 of 5 stars3.53.00.00.00.01.71.3ORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics3.00BuyN/AN/ACOCPCocrystal Pharma3.00Buy$10.00525.04% UpsideORMPOramed PharmaceuticalsN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/ACurrent Analyst RatingsLatest ORMP, COCP, PVOTF, ATXI, and VBLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/20/2024COCPCocrystal PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$0.03 per shareN/ACOCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/AORMPOramed Pharmaceuticals$1.34M68.94N/AN/A$4.04 per share0.56PVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/AVBLTVascular Biogenics$660K642.29N/AN/A$0.32 per share17.06Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$1.27N/A∞N/AN/AN/A-335.11%5/10/2024 (Estimated)COCPCocrystal Pharma-$17.98M-$1.99N/AN/AN/AN/A-59.62%-54.62%5/20/2024 (Estimated)ORMPOramed Pharmaceuticals$5.53M$0.1416.29∞N/AN/A-7.15%-5.70%5/9/2024 (Estimated)PVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/AVBLTVascular Biogenics-$32.30M-$0.21N/A∞N/AN/A-73.45%-54.11%N/ALatest ORMP, COCP, PVOTF, ATXI, and VBLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023COCPCocrystal Pharma-$0.57-$0.44+$0.13-$0.44N/AN/A3/18/2024Q4 2023ATXIAvenue TherapeuticsN/A$0.56+$0.56$0.56N/AN/A3/6/2024Q4 2023ORMPOramed Pharmaceuticals-$0.12-$0.08+$0.04-$0.49N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/AVBLTVascular BiogenicsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A1.551.55COCPCocrystal PharmaN/A8.928.92ORMPOramed PharmaceuticalsN/A3.063.06PVOTFBetterLife PharmaN/A3.623.62VBLTVascular BiogenicsN/A4.634.63OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%COCPCocrystal Pharma6.72%ORMPOramed Pharmaceuticals12.73%PVOTFBetterLife PharmaN/AVBLTVascular Biogenics0.96%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%COCPCocrystal Pharma25.06%ORMPOramed Pharmaceuticals12.00%PVOTFBetterLife Pharma34.77%VBLTVascular Biogenics6.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics344.26 million43.46 millionNot OptionableCOCPCocrystal Pharma1210.17 million7.62 millionNot OptionableORMPOramed Pharmaceuticals1240.52 million35.66 millionOptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableVBLTVascular Biogenics777.64 million72.88 millionOptionableORMP, COCP, PVOTF, ATXI, and VBLT HeadlinesSourceHeadlineTommy Garten elected to VBL Hall of Fametherecorderonline.com - March 28 at 1:31 PMControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie systemnature.com - February 21 at 3:29 PMVascular News and Researchnews-medical.net - November 25 at 2:28 PMVascular Biogenics (VBLT) Price Target Increased by 160.00% to 13.26msn.com - November 3 at 12:39 AMNotable Labs Closes Merger Transaction With VBL Therapeuticsfinance.yahoo.com - October 16 at 3:55 PMVBL Therapeutics Announces Results of Annual and Special Shareholder Meetingfinance.yahoo.com - October 12 at 3:13 PMVBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meetingfinance.yahoo.com - October 4 at 8:40 AMVascular Biogenics Rises on Presentation Hypefinance.yahoo.com - September 9 at 12:00 PMVBLT Stock Sees Decline of Approximately -0.22% in Last Five Daysknoxdaily.com - September 7 at 9:15 PMVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECfinance.yahoo.com - September 6 at 7:30 PMVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTbusinesswire.com - August 28 at 7:00 PMVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTbusinesswire.com - August 28 at 3:04 PMVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - August 14 at 8:09 AMMonitoring Vascular Biogenics Ltd. (VBLT) after recent insider movementsknoxdaily.com - July 26 at 4:10 PMVascular Biogenics (NASDAQ: VBLT)fool.com - July 23 at 5:52 PMRecent Insider Activity Suggests Potential Gains for Vascular Biogenics Ltd. (VBLT)knoxdaily.com - July 12 at 4:20 PMVBLT Stock Sees Decline of Approximately -4.31% in Last Five Daysknoxdaily.com - July 7 at 2:11 PMDays-to-cover ratio for VBLT surges to 0.84 due to rise in short interestknoxdaily.com - June 23 at 8:26 PMThe Role of Peripheral Arterial Disease in the Pathogenesis of Diabetic Foot Disease: When to Refer for Vascular Surgerymedscape.com - May 18 at 1:35 AMVBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 15 at 8:03 PMDeveloping a Patient-Centered Approach to Vascular Access Device Selectionmedscape.com - May 10 at 8:52 AMCADASIL: The Most Common Hereditary Subcortical Vascular Dementiamedscape.com - May 5 at 1:05 AMAspirin in Stroke Prevention in Nonvalvular Atrial Fibrillation and Stable Vascular Diseasemedscape.com - May 2 at 8:00 PMVascular Biogenics Stock (NASDAQ:VBLT), Dividendsbenzinga.com - April 4 at 1:52 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvenue TherapeuticsNASDAQ:ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.Cocrystal PharmaNASDAQ:COCPCocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Oramed PharmaceuticalsNASDAQ:ORMPOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.BetterLife PharmaOTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.Vascular BiogenicsNASDAQ:VBLTVascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.